Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Revenue (2016 - 2025)

Spero Therapeutics' Revenue history spans 10 years, with the latest figure at $47.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 90325.0% year-over-year to $47.0 million; the TTM value through Dec 2025 reached $70.1 million, up 193.99%, while the annual FY2025 figure was $47.0 million, 12577.36% up from the prior year.
  • Revenue reached $47.0 million in Q4 2025 per SPRO's latest filing, up from $5.4 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $72.1 million in Q4 2023 to a low of -$12.4 million in Q4 2021.
  • Average Revenue over 5 years is $10.5 million, with a median of $3.8 million recorded in 2021.
  • Peak YoY movement for Revenue: plummeted 99.93% in 2024, then surged 90325.0% in 2025.
  • A 5-year view of Revenue shows it stood at -$12.4 million in 2021, then skyrocketed by 234.83% to $16.8 million in 2022, then skyrocketed by 330.08% to $72.1 million in 2023, then tumbled by 99.93% to $52000.0 in 2024, then soared by 90325.0% to $47.0 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Revenue are $47.0 million (Q4 2025), $5.4 million (Q3 2025), and $11.8 million (Q2 2025).